Lower Cost
Lower pathway cost through smarter use of diagnostic capacity.
Uromonitor® can support a more efficient bladder cancer surveillance model by helping services reduce unnecessary cystoscopy demand, avoidable downstream procedures and pressure on constrained clinical capacity.
The financial case starts with unnecessary cystoscopy demand.
Bladder cancer surveillance places recurring pressure on urology services. Many cystoscopies are essential, but high-volume routine surveillance can create avoidable cost and capacity strain. A governed molecular urine pathway can help providers use invasive investigation more selectively.
Fewer unnecessary cystoscopies
Uromonitor can support selection of patients who may not require immediate invasive investigation, where clinical risk and pathway rules support that decision.
Less downstream pressure
Better triage can reduce avoidable appointments, repeat sampling, administrative burden and unnecessary follow-on procedures.
Better use of specialist time
Clinical capacity can be directed towards higher-risk patients and urgent suspected cancer pathways, improving productivity without weakening governance.
Cost reduction comes from redesigning the pathway, not cutting corners.
Uromonitor should be used as a governed adjunct to cystoscopy and cytology. The value comes from using existing capacity more intelligently.
Current surveillance demand
Routine follow-up creates repeated cystoscopy pressure over time.
Risk-adapted triage
Lower and higher-risk surveillance episodes are separated more clearly.
Reflex Uromonitor
Molecular urine testing adds another decision signal into the pathway.
Selective cystoscopy
Cystoscopy is focused where clinical and molecular concern is higher.
Cost and time saving
Avoidable procedures and low-yield appointments can be reduced.
Lower cost is achieved by reducing low-yield activity.
The strongest cost argument is not simply the price of a test. It is the effect on the whole pathway: fewer unnecessary cystoscopies, fewer avoidable downstream procedures and more efficient use of specialist clinical time.
Lower cost still needs clinical governance.
Cost reduction only matters if patient safety and clinical confidence are maintained. Uromonitor should sit inside a defined pathway with patient-selection rules, escalation criteria, laboratory governance and outcome audit.
Discuss pathway cost reduction.
Speak to Progen Diagnostics about how Uromonitor could support cystoscopy capacity release, reduced avoidable procedures and a more efficient bladder cancer surveillance pathway.